Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07533994

ACOD1 as a Prognostic Marker for Sepsis

The Role of Acod1 in Prognostic Evaluation of Sepsis: A Prospective, Single-Center, Observational Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
52 (estimated)
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Accepted

Summary

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, with high morbidity and mortality worldwide. Reliable biomarkers are needed for early risk stratification and outcome prediction. This prospective, single-center, observational study aims to evaluate the prognostic value of Acod1 gene expression in peripheral blood mononuclear cells (PBMCs) from septic patients. The primary objective is to assess the sensitivity and specificity of ACOD1 expression measured by RT-qPCR within 24-48 hours of ICU admission for predicting sepsis mortality. Secondary objectives include correlating ACOD1 expression with the SOFA score, and comparing its predictive performance against established clinical markers and scores such as APACHE II, SOFA, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), arterial lactate, and IL-1β expression. The study will also report in-hospital mortality. Findings may support ACOD1 as a novel molecular biomarker for early prognostic assessment in sepsis.

Conditions

Interventions

TypeNameDescription
OTHERBlood draw for lab testing.No clinical or pharmacological intervention.

Timeline

Start date
2025-10-01
Primary completion
2026-06-01
Completion
2026-06-01
First posted
2026-04-16
Last updated
2026-04-16

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT07533994. Inclusion in this directory is not an endorsement.